CUA 2017: Analysis of Real-World use of Radium-223 in Ontario

Toronto, Ontario ( Dr. Urban Emmenegger and colleagues presented their study assessing real-world utilization of the alpha emitter Radium-223 at the prostate cancer poster session at the 2017 CUA annual meeting. Based on the ALSYMPCA trial, we know that Radium-223 improves survival and delays skeletal related events (SREs) among patients with metastatic castration-resistant prostate cancer (mCRPC) to the bone.1

However, even in the ALSYMPCA trial, only 63% of patients received the maximum six cycles of Radium-223, whereas in the real-world setting patients are typically older with more comorbidities than those participating in clinical trials. As such, the objective of this study was to assess the real-world use of Radium-223 in four Ontario cancer centers.

This retrospective study included 199 men with mCRPC patients receiving ≥1 dose of Radium-223 from January 2015 to April 2016. The co-primary outcomes were number of patients receiving all six Radium-223 cycles and reasons for treatment discontinuations for men receiving <6 cycles. Secondary outcomes included baseline disease characteristics, proportion of patients achieving a >30% PSA response, >50% PSA response and alkaline phosphatase (ALP) normalization, as well as adverse events. Among included patients, the median age was 75 years (range 52-93), median PSA was 76.4 ng/mL (range 0.8-6500), 21% of patients had ALP ≥220 U/L (median 113 U/L), and median hemoglobin was 12 g/dL (range 1.2-16.1). The most common prior treatment was docetaxel (50% of patients). Ninety-one patients (46%) received the maximum six cycles. The main reasons for early treatment discontinuation included symptomatic disease progression (38%), symptom concern (11%), and neutropenia (11%). In patients receiving ≥3 cycles of Radium-223, 13% of patients had >30% PSA decline, 6% had >50% PSA decline, and ALP normalization was observed in 25% of patients with baseline ALP elevation. There were no unexpected adverse events.

In conclusion, in an older, real world population with comparable disease characteristics to those enrolled in ALSYMPCA, Radium-223 was safely administered but the proportion of patients receiving all six cycles of treatment was low (and lower compared to patients in ALSYMPCA). Future pooled analyses on a larger scale would increase the sample size to allow for analysis of factors predicting early Radium-223 termination.

Presented By: Urban Emmenegger, MD, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

Co-Authors: Sierra Cheng, Leigha Rowbottom, Rachel McDonald, Ronald Chow, Neil E. Fleshner, Pawel Zalewski, Anil Kapoor, Edward Chow

Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre  Twitter: @zklaassen_md at the  72nd Canadian Urological Association Annual Meeting - June 24 - 27, 2017 - Toronto, Ontario, Canada

1. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013 Jul 18;369(3):213-223.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.